Eurofins Scientific has acquired Sinensis Life Sciences BV, a provider of pharmaceutical product testing and cGMP quality control (QC) services in the Netherlands.

Sinensis has a strong position in both microbiology and chemistry testing for biopharmaceutical products in the domestic market, and has a presence in Europe, Asia and the U.S. The company employs about 150 staff, serving the pharmaceutical and biotechnology industries throughout the Netherlands.

Since inception, Sinensis says it has consistently grown above Eurofins' annual organic growth objective, and expects to generate revenues in excess of €13.5 million for 2015, the majority of which from biopharmaceutical products testing. The company is also active in biosafety testing and biological R&D, chemical R&D, and in cGMP manufacturing.

Sinensis' competencies are consistent with Eurofins' biopharmaceutical testing capabilities, and specifically with the competencies of Eurofins Lancaster. The acquisition strengthens the group's geographical footprint and its position as a market leader in this growing pharmaceutical services segment. The acquisition also reinforces the group's platform to further accelerate the deployment of the most advanced testing methodologies to support the pharmaceutical and biotechnology industries across the entire drug development cycle in Europe.  

“The acquisition of Sinensis further strengthens Eurofins' global leadership in the rapidly-growing pharmaceutical products testing market,” said Gilles Martin, chief executive officer, Eurofins. “We look forward to strengthening Sinensis' testing portfolio and operating footprint by providing access to the full range of services and capabilities of the Eurofins Group.”